Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialThomas L Holland, Robert C. Hyzy, Andrew M. Vekstein et al.|The Lancet Respiratory Medicine|2022Cited by 127
Convergent and divergent immune aberrations in COVID-19, post-COVID-19-interstitial lung disease, and idiopathic pulmonary fibrosisBochra Tourki, Jose D. Herazo‐Maya, Minxue Jia et al.|American Journal of Physiology-Cell Physiology|2024Cited by 9
A 50-gene high-risk profile predictive of COVID-19 and Idiopathic Pulmonary Fibrosis mortality originates from a genomic imbalance in monocyte and T-cell subsets that reverses in survivors with post-COVID-19 Interstitial Lung DiseaseBochra Tourki, Jose D. Herazo‐Maya, Minxue Jia et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 1